[Paronychia in patients infected with HIV treated with indinavir]. 2001

M J García García, and L E Morano Amado, and F Allegue Rodríguez, and C Miralles Alvarez, and A Ocampo Hermida
Servicios de Medicina Interna-Infecciosas, Hospital do Meixoeiro, Vigo. grandiella@mixmail.com

A retrospective study of cases of paronychia associated with anti-retroviral therapy diagnosed in two general hospitals is here reported. Lesions appeared from 3 and 48 months after institution of therapy. At diagnosis, 84.6% of patients were on indinavir therapy. CD4 values ranged from 120 and 1,332 cells/mm3 and viral load was lower than 200 copies/ml in 92.3 of cases. Conservative therapy was applied in 7 patients and surgery in 6. In all patients indinavir therapy was discontinued, and cure was achieved 16 weeks later. The "retinoid" effect of indinavir is discussed as likely pathogenic explanation for this complications. We advocate for topic therapy and change of anti-retroviral therapy, reserving surgery for patients not responding to therapy. Pain and functional limitation caused by this non uncommon complication (1.6% of our patients treated with anti-retroviral agents) makes its knowledge necessary and an active search by clinicians in patients receiving indinavir therapy.

UI MeSH Term Description Entries
D008297 Male Males
D010304 Paronychia An inflammatory reaction involving the folds of the skin surrounding the fingernail. It is characterized by acute or chronic purulent, tender, and painful swellings of the tissues around the nail, caused by an abscess of the nail fold. The pathogenic yeast causing paronychia is most frequently Candida albicans. Saprophytic fungi may also be involved. The causative bacteria are usually Staphylococcus, Pseudomonas aeruginosa, or Streptococcus. (Andrews' Diseases of the Skin, 8th ed, p271) Paronychias
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV
D019469 Indinavir A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. Crixivan,Indinavir Sulfate,Indinavir, Sulfate (1:1),L-735 524,L-735,524,MK-639,L 735 524,L 735,524,L735 524,L735,524,MK 639,MK639,Sulfate, Indinavir

Related Publications

M J García García, and L E Morano Amado, and F Allegue Rodríguez, and C Miralles Alvarez, and A Ocampo Hermida
January 2001, Przeglad lekarski,
M J García García, and L E Morano Amado, and F Allegue Rodríguez, and C Miralles Alvarez, and A Ocampo Hermida
October 2000, Archivos espanoles de urologia,
M J García García, and L E Morano Amado, and F Allegue Rodríguez, and C Miralles Alvarez, and A Ocampo Hermida
June 1998, The New England journal of medicine,
M J García García, and L E Morano Amado, and F Allegue Rodríguez, and C Miralles Alvarez, and A Ocampo Hermida
January 2006, Clinical nephrology,
M J García García, and L E Morano Amado, and F Allegue Rodríguez, and C Miralles Alvarez, and A Ocampo Hermida
January 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
M J García García, and L E Morano Amado, and F Allegue Rodríguez, and C Miralles Alvarez, and A Ocampo Hermida
January 2007, AIDS (London, England),
M J García García, and L E Morano Amado, and F Allegue Rodríguez, and C Miralles Alvarez, and A Ocampo Hermida
July 2001, AIDS (London, England),
M J García García, and L E Morano Amado, and F Allegue Rodríguez, and C Miralles Alvarez, and A Ocampo Hermida
January 1999, AIDS patient care and STDs,
M J García García, and L E Morano Amado, and F Allegue Rodríguez, and C Miralles Alvarez, and A Ocampo Hermida
October 2007, European journal of clinical pharmacology,
M J García García, and L E Morano Amado, and F Allegue Rodríguez, and C Miralles Alvarez, and A Ocampo Hermida
April 2003, AIDS (London, England),
Copied contents to your clipboard!